<DOC>
	<DOCNO>NCT00002051</DOCNO>
	<brief_summary>Examine ability thymopentin ( Timunox ) : Reduce amount and/or frequency virus isolation . Stimulate immune system alter clinical finding patient infect HIV yet AIDS .</brief_summary>
	<brief_title>Double Blind Study Thymopentin Effects Patients With HIV-1 Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Thymopentin</mesh_term>
	<criteria>Inclusion Criteria Concurrent Treatment : Allowed : Aerosolized pentamidine . Prior Medication : Allowed : Aerosolized pentamidine . Exclusion Criteria Coexisting Condition : Patients follow exclude : AIDS define CDC ( except HIV `` waste syndrome '' ) . Significant hepatic disease . Thrombocytopenia ( &lt; 75000 platelets/mm3 ) . Abnormal chest xray ( indicative active disease ( opportunistic infection ) ) within 30 day prior entry . Hemophilia A B hematologic disorder require current previous administration blood product . Known hypersensitivity thymopentin . Prior Medication : Excluded within 30 day study entry : Immunomodulatory experimental therapy . Excluded within 90 day study entry : Zidovudine ( AZT ) . Patients must : AIDS define CDC ( except HIV `` waste syndrome '' ) . Significant hepatic disease . Thrombocytopenia ( &lt; 75000 platelets/mm3 ) . Patients follow condition include : Seropositive HIV1 ( ELISA assay ) confirm Western blot . HIV1 p24 antigen must detect supernatant fluid cocultures patient 's peripheral blood monocyte ( PBMC ) two separate occasion . HIV `` waste syndrome '' . Must voluntarily sign consent . History intravenous drug abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 1989</verification_date>
	<keyword>Thymopentin</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
</DOC>